Cartesian Therapeutics, Inc. (RNAC) Return on equity 2016–2022
Cartesian Therapeutics, Inc. (RNAC) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
37.7%FY2022 · since FY2016: -65.9% → 37.7%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2022 | 37.7% | +151.8 pp |
| FY2021 | -114.1% | — |
| FY2019 | -659.2% | — |
| FY2017 | -126.1% | -60.2 pp |
| FY2016 | -65.9% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice
More RNAC financial trends
RNAC RevenueRNAC Net incomeRNAC Net marginRNAC Gross profitRNAC Gross marginRNAC Operating incomeRNAC Operating marginRNAC Operating cash flowRNAC Free cash flowRNAC Capital expendituresRNAC Stock buybacksRNAC Dividends paidRNAC Total assetsRNAC Total liabilitiesRNAC Shareholders’ equityRNAC overview →